Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Further expansion of cost reduction programme

Proposed site consolidations expected to deliver c. £2.0m EBITDA improvement

Paris, France, Eastleigh and Manchester, UK – 14 November 2024 - Novacyt (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and
services, announces proposed changes to its operational footprint which would lead to a further consolidation of
global facilities and is expected to improve the Group’s EBITDA position by an additional £2.0m annually.

Proposed closure of Eastleigh site
Following the refocus of the Primer Design business on the Research Use Only market, and a review of operations
as part of a programme to implement further significant cost savings, the Company announces that it has begun a
consultation process which may result in the closure of its Eastleigh site and relocation of the business to the Group’s
Manchester facility. A further announcement will be released in respect of the outcome of the consultation process
in due course.

Transfer of Canada manufacturing operations to Manchester
In addition, the Company is in the process of closing Yourgene Health Canada’s manufacturing site and relocating
its operations to the Group’s Manchester facility, where the manufacture of Ranger® instrumentation and
consumables will take place. Yourgene Health Canada’s research and development facility on Vancouver Island,
responsible for developing improvements and updates to the Ranger® Technology portfolio, will remain in place.

Should the relocation of the Eastleigh operations proceed, the combined consolidations are expected to improve
the Group’s EBITDA position by c. £2.0m annually. A cash restructuring charge of c. £1.5m is expected in connection
with the combined closures.

Lyn Rees, CEO of Novacyt, commented: “Whilst a difficult decision, consolidating our sites and having the Group’s
manufacturing based at our Manchester facility would provide a significant reduction in our cost base, in-line with
our strategy. If completed, we believe that this move would benefit the entirety of the Novacyt business and
represent a key step in right-sizing our cost base and better positioning us to deliver future growth, and we have the
capacity and expertise at our Manchester facility to ensure that there is no impact on our customers as a result of
any site consolidations.

“We will begin the consultation regarding the Eastleigh site closure in due course and will provide an update to the
market following the conclusion of the process.”

Contacts

Novacyt SA https://novacyt.com/investors
Lyn Rees, Chief Executive Officer Via Walbrook PR
Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or novacyt@walbrookpr.com
Paul McManus / Lianne Applegarth +44 (0)7980 541 893 / +44 (0)7584 391 303
Phillip Marriage / Alice Woodings +44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies
and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health
and environmental.

The Company is divided into three business segments:

Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services
focused on three therapeutic areas:
• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
• Precision Medicine: DPYD genotyping assay
• Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid
PCR machines, including:
• Ranger® Technology: automated DNA sample preparation and target enrichment
technology
• genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

Research Use Only Range of services for the life sciences industry:
• Design, manufacture, and supply of high-performance qPCR assays and workflows
for use in human health, agriculture, veterinary and environmental, to support
global health organisations and the research industry
• Pharmaceutical research services: whole genome sequencing (WGS) / whole
exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester),
Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the
London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).

For more information, please refer to the website: www.novacyt.com